Workflow
奥赛康(002755) - 2025 Q3 - 季度财报
ASK PHARMASK PHARM(SZ:002755)2025-10-28 08:10

Revenue and Profitability - The company's revenue for Q3 2025 was CNY 426,481,422.98, a decrease of 7.67% compared to the same period last year[5] - Net profit attributable to shareholders increased by 23.15% to CNY 63,327,205.89 for Q3 2025, and by 75.81% to CNY 223,314,336.76 for the year-to-date[5] - Basic and diluted earnings per share for Q3 2025 were CNY 0.07, reflecting a 16.67% increase year-on-year[5] - Total operating revenue for the current period reached ¥1,433,894,250.94, an increase of 3.0% compared to ¥1,384,454,586.25 in the previous period[16] - Net profit for the current period was ¥207,641,414.84, up 89.3% from ¥109,679,781.38 in the previous period[17] - Earnings per share increased to ¥0.24, compared to ¥0.14 in the previous period, representing a growth of 71.4%[17] Assets and Liabilities - Total assets at the end of Q3 2025 reached CNY 4,436,198,585.09, representing a 9.60% increase from the end of the previous year[5] - Total current assets increased to ¥2,941,483,839.60 from ¥2,568,164,247.66, representing a growth of approximately 14.5%[13] - Total liabilities increased to ¥1,164,638,906.87 from ¥905,387,149.91, reflecting an increase of approximately 28.6%[14] - Non-current assets totaled ¥1,494,714,745.49, slightly up from ¥1,479,464,276.37, indicating a growth of about 1.6%[14] - The total liabilities and equity reached ¥4,436,198,585.09, up from ¥4,047,628,524.03, indicating an increase of 9.6%[15] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 601,826,250.71, an increase of 34.47% compared to the same period last year[5] - Cash flow from operating activities generated ¥601,826,250.71, an increase of 34.3% from ¥447,539,961.30 in the previous period[18] - Cash inflow from investment activities totaled ¥3,144,198,514.18, compared to ¥2,913,522,957.93 in the previous period, marking an increase of 7.9%[18] - The company reported a net cash outflow from investment activities of ¥467,786,557.39, worsening from a net outflow of ¥330,534,996.03 in the previous period[18] - Cash inflow from financing activities totaled $77 million, up from $40 million in the previous period, indicating a 92.5% increase[19] - Cash outflow from financing activities amounted to $175.2 million, compared to $86.7 million previously, representing a 102.5% increase[19] - Net cash flow from financing activities was -$98.2 million, worsening from -$46.7 million in the prior period[19] - The net increase in cash and cash equivalents for the period was $34.67 million, down from $74.49 million in the previous period[19] - The ending balance of cash and cash equivalents reached $1.35 billion, an increase from $1.11 billion at the end of the previous period[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 27,238[10] - The largest shareholder, Nanjing Aosaikang Investment Management Co., Ltd., holds 34.20% of shares, totaling 317,470,588 shares[10] - The company has not reported any changes in the top 10 shareholders due to margin trading activities[11] - There are no preferred shareholders or related party transactions reported in the current period[12] Other Financial Metrics - The company reported a significant increase in prepayments, which rose by 143.55% to CNY 19,740,360.27, primarily due to increased material and R&D prepayments[8] - The company experienced a 206.70% decline in investment income, reporting a loss of CNY 10,398,182.78, mainly due to the disposal of certain investments[8] - The company’s total equity attributable to shareholders increased by 4.64% to CNY 3,204,831,334.00 compared to the end of the previous year[5] - The total equity remains stable at ¥928,160,351.00, unchanged from the previous period[14] - The company’s minority interests decreased to ¥66,728,344.22 from ¥79,589,419.92, a decline of 16.1%[15] Audit and Reliability - The third quarter financial report was not audited, which may affect the reliability of the reported figures[20]